Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project

Background Influenza is an infectious disease causing a high annual economic and public health burden. The most efficient management of the disease is through prevention with vaccination. Many influenza vaccines are available, with varying efficacy and cost, targeting different age groups. Therefore, strategic decision-making about which vaccine to deliver to whom is warranted to improve efficiency. Objective We present the use of a constrained optimization (CO) model to evaluate targeted strategies for providing influenza vaccines in three adult age groups in the USA. Methods CO was considered for identifying an influenza vaccine provision strategy that maximizes the benefits at constrained annual budgets, by prioritizing vaccines based on return on investment. The approach optimizes a set of predefined outcome measures over several years resulting from an increasing investment using the best combination of influenza vaccines. Results Results indicate the importance of understanding the relative differences in benefits for each vaccine type within and across age groups. Scenario and threshold analyses demonstrate the impact of changing budget distribution over time, price setting per vaccine type, and selection of outcome measure to optimize. Conclusion Significant gains in cost efficiency can be realized for a decision maker using a CO model, especially for a disease like influenza with many vaccine options. Testing the model under different scenarios offers powerful insights into maximum achievable benefit overall and per age group within the predefined constraints of a vaccine budget.

[1]  L. Grohskopf,et al.  Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices — United States , 2016 – 17 Influenza Season , 2016 .

[2]  C. Bauch,et al.  Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis , 2013, BMC Medicine.

[3]  J. McLaughlin,et al.  Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013 , 2015, The Journal of Primary Prevention.

[4]  Maarten J. IJzerman,et al.  Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  C. Reed,et al.  Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States , 2015, PloS one.

[6]  L. Grohskopf,et al.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 Influenza Season , 2015, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[7]  K. Subbarao,et al.  Influenza vaccines: challenges and solutions. , 2015, Cell host & microbe.

[8]  M. Stockwell,et al.  Economic burden of seasonal influenza in the United States. , 2018, Vaccine.

[9]  F. Ansaldi,et al.  Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden , 2016, Journal of preventive medicine and hygiene.

[10]  O. Pybus,et al.  A naturally protective epitope of limited variability as an influenza vaccine target , 2018, Nature Communications.

[11]  R. Rappuoli,et al.  2. How is the economic assessment of vaccines performed today? , 2017, Journal of market access & health policy.

[12]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[13]  Fluad--an adjuvanted seasonal influenza vaccine for older adults. , 2016, The Medical letter on drugs and therapeutics.

[14]  Anke Richter,et al.  Optimal Allocation of Resources across Four Interventions for Type 2 Diabetes , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[15]  E. Thommes,et al.  Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach , 2016, Human vaccines & immunotherapeutics.

[16]  L. Grohskopf,et al.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 Influenza Season , 2017, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[17]  J. Eiros,et al.  Cell culture-derived flu vaccine: Present and future , 2018, Human vaccines & immunotherapeutics.

[18]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[19]  C. Bridges,et al.  The annual impact of seasonal influenza in the US: measuring disease burden and costs. , 2007, Vaccine.

[20]  L. Finelli,et al.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[21]  F. Hayden,et al.  Epidemic influenza--responding to the expected but unpredictable. , 2013, The New England journal of medicine.

[22]  B. Standaert,et al.  Optimising the introduction of multiple childhood vaccines in Japan: A model proposing the introduction sequence achieving the highest health gains. , 2017, Health policy.

[23]  Yi Guan,et al.  Influenza: Emergence and Control , 2004, Journal of Virology.

[24]  R. Belshe The need for quadrivalent vaccine against seasonal influenza. , 2010, Vaccine.

[25]  Baudouin Standaert,et al.  Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program , 2012, PharmacoEconomics.

[26]  A. Gordon,et al.  The Burden of Influenza: a Complex Problem , 2018, Current Epidemiology Reports.

[27]  Maarten J. IJzerman,et al.  Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  C. Adebamowo,et al.  Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. , 2011, The Lancet. Oncology.

[29]  A. Culyer,et al.  Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  Ivo M Foppa,et al.  Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness , 2018, Influenza and other respiratory viruses.

[31]  Carrie Reed,et al.  Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011 , 2013, PloS one.

[32]  M. Cox,et al.  Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older , 2017, The New England journal of medicine.

[33]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[34]  Ruhul A. Sarker,et al.  Optimization Modelling: A Practical Approach , 2007 .

[35]  John Earl,et al.  Efficacy of high-dose versus standard-dose influenza vaccine in older adults. , 2014, The New England journal of medicine.